Radiosensitization of two murine fibrosarcomas with 6-thioguanine

Jae Ho Kim, Alan A. Alfieri, Sang Hie Kim, Seung S. Hong

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

in vivo murine tumor experiments were carried out to determine whether 6-thioguanine (6-TG) could enhance the cytotoxic effects of radiation on tumors. The combined effects of single and fractionated x-irradiation were evaluated on the transplanted methylcholanthrene induced fibrosarcoma (Meth-A) in BALB/c mice, a moderately radio-responsive tumor and on the radiation induced fibrosarcoma (RIF) in C3H/He mice, a highly radioresistant tumor. The combined treatment of single administration of 6-TG (25 mg/kg) and of x-irradiation (20 Gy) on Meth-A tummor produced more than 90% tumor control, whereas the radiation alone resulted in less than 5% tumor control. The radiosensitizing effect by 6-TG was higher when the drug was administered either I to 8 hr prior to or 24 hr after x-irradiation. The dose modification factor of single dose 6-TG (10 mg/kg) is estimated to be 1.47 for Meth-A tumor and 1.25 for RIF tumor. The tumor control rates of fractionated irradiation alone and with concomitant 6-TG in Meth-A tumors were 14% and 59%, respectively. Based on the studies reported here and well documented pharmacokinetics in humans, it is suggested that combined radiation therapy and 6-TG may provide an enhanced therapeutic effect even in tumor varieties where the drug has no apparent anti-tumor activity on non-irradiated cells.

Original languageEnglish (US)
Pages (from-to)583-586
Number of pages4
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume18
Issue number3
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Thioguanine
Fibrosarcoma
tumors
Neoplasms
irradiation
radiation
Radiation
mice
drugs
Radiation-Sensitizing Agents
dosage
Methylcholanthrene
Inbred C3H Mouse
Radiation Effects
Therapeutic Uses
Radio
Pharmaceutical Preparations
radiation therapy

Keywords

  • 6-Thioguanine
  • Murine tumors
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Radiosensitization of two murine fibrosarcomas with 6-thioguanine. / Kim, Jae Ho; Alfieri, Alan A.; Kim, Sang Hie; Hong, Seung S.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 18, No. 3, 1990, p. 583-586.

Research output: Contribution to journalArticle

Kim, Jae Ho ; Alfieri, Alan A. ; Kim, Sang Hie ; Hong, Seung S. / Radiosensitization of two murine fibrosarcomas with 6-thioguanine. In: International Journal of Radiation Oncology, Biology, Physics. 1990 ; Vol. 18, No. 3. pp. 583-586.
@article{4822d56e9fbe4d3e9f806e77dc1120be,
title = "Radiosensitization of two murine fibrosarcomas with 6-thioguanine",
abstract = "in vivo murine tumor experiments were carried out to determine whether 6-thioguanine (6-TG) could enhance the cytotoxic effects of radiation on tumors. The combined effects of single and fractionated x-irradiation were evaluated on the transplanted methylcholanthrene induced fibrosarcoma (Meth-A) in BALB/c mice, a moderately radio-responsive tumor and on the radiation induced fibrosarcoma (RIF) in C3H/He mice, a highly radioresistant tumor. The combined treatment of single administration of 6-TG (25 mg/kg) and of x-irradiation (20 Gy) on Meth-A tummor produced more than 90{\%} tumor control, whereas the radiation alone resulted in less than 5{\%} tumor control. The radiosensitizing effect by 6-TG was higher when the drug was administered either I to 8 hr prior to or 24 hr after x-irradiation. The dose modification factor of single dose 6-TG (10 mg/kg) is estimated to be 1.47 for Meth-A tumor and 1.25 for RIF tumor. The tumor control rates of fractionated irradiation alone and with concomitant 6-TG in Meth-A tumors were 14{\%} and 59{\%}, respectively. Based on the studies reported here and well documented pharmacokinetics in humans, it is suggested that combined radiation therapy and 6-TG may provide an enhanced therapeutic effect even in tumor varieties where the drug has no apparent anti-tumor activity on non-irradiated cells.",
keywords = "6-Thioguanine, Murine tumors, Radiation therapy",
author = "Kim, {Jae Ho} and Alfieri, {Alan A.} and Kim, {Sang Hie} and Hong, {Seung S.}",
year = "1990",
doi = "10.1016/0360-3016(90)90064-Q",
language = "English (US)",
volume = "18",
pages = "583--586",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Radiosensitization of two murine fibrosarcomas with 6-thioguanine

AU - Kim, Jae Ho

AU - Alfieri, Alan A.

AU - Kim, Sang Hie

AU - Hong, Seung S.

PY - 1990

Y1 - 1990

N2 - in vivo murine tumor experiments were carried out to determine whether 6-thioguanine (6-TG) could enhance the cytotoxic effects of radiation on tumors. The combined effects of single and fractionated x-irradiation were evaluated on the transplanted methylcholanthrene induced fibrosarcoma (Meth-A) in BALB/c mice, a moderately radio-responsive tumor and on the radiation induced fibrosarcoma (RIF) in C3H/He mice, a highly radioresistant tumor. The combined treatment of single administration of 6-TG (25 mg/kg) and of x-irradiation (20 Gy) on Meth-A tummor produced more than 90% tumor control, whereas the radiation alone resulted in less than 5% tumor control. The radiosensitizing effect by 6-TG was higher when the drug was administered either I to 8 hr prior to or 24 hr after x-irradiation. The dose modification factor of single dose 6-TG (10 mg/kg) is estimated to be 1.47 for Meth-A tumor and 1.25 for RIF tumor. The tumor control rates of fractionated irradiation alone and with concomitant 6-TG in Meth-A tumors were 14% and 59%, respectively. Based on the studies reported here and well documented pharmacokinetics in humans, it is suggested that combined radiation therapy and 6-TG may provide an enhanced therapeutic effect even in tumor varieties where the drug has no apparent anti-tumor activity on non-irradiated cells.

AB - in vivo murine tumor experiments were carried out to determine whether 6-thioguanine (6-TG) could enhance the cytotoxic effects of radiation on tumors. The combined effects of single and fractionated x-irradiation were evaluated on the transplanted methylcholanthrene induced fibrosarcoma (Meth-A) in BALB/c mice, a moderately radio-responsive tumor and on the radiation induced fibrosarcoma (RIF) in C3H/He mice, a highly radioresistant tumor. The combined treatment of single administration of 6-TG (25 mg/kg) and of x-irradiation (20 Gy) on Meth-A tummor produced more than 90% tumor control, whereas the radiation alone resulted in less than 5% tumor control. The radiosensitizing effect by 6-TG was higher when the drug was administered either I to 8 hr prior to or 24 hr after x-irradiation. The dose modification factor of single dose 6-TG (10 mg/kg) is estimated to be 1.47 for Meth-A tumor and 1.25 for RIF tumor. The tumor control rates of fractionated irradiation alone and with concomitant 6-TG in Meth-A tumors were 14% and 59%, respectively. Based on the studies reported here and well documented pharmacokinetics in humans, it is suggested that combined radiation therapy and 6-TG may provide an enhanced therapeutic effect even in tumor varieties where the drug has no apparent anti-tumor activity on non-irradiated cells.

KW - 6-Thioguanine

KW - Murine tumors

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0025371792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025371792&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(90)90064-Q

DO - 10.1016/0360-3016(90)90064-Q

M3 - Article

VL - 18

SP - 583

EP - 586

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -